Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan
Authors
Discussion
Loading...
Member takes
Implication
Post-marketing surveillance demonstrates favorable ponatinib efficacy alongside arterial occlusive events in leukemia patients, highlighting the need for vascular monitoring in high-risk groups.
Key Points
- Ponatinib demonstrated favorable clinical efficacy across resistant leukemia cohorts, but arterial occlusive events occurred in a subset of patients with preexisting vascular risks.
- Arterial occlusive events occurred in 6.49% of patients, while the two-year cumulative major molecular response rate reached 67.2% in chronic-phase chronic myeloid leukemia.
- Post-marketing all-case surveillance highlights the necessity of monitoring arterial occlusive events during ponatinib therapy, particularly in older adults with predisposing factors.
Cite This Study
Takahashi et al. (2024) studied this question.